FR23C1048I1 - Agonistes de recepteur de ghreline pour la traitemnet de la cachexia - Google Patents

Agonistes de recepteur de ghreline pour la traitemnet de la cachexia

Info

Publication number
FR23C1048I1
FR23C1048I1 FR23C1048C FR23C1048C FR23C1048I1 FR 23C1048 I1 FR23C1048 I1 FR 23C1048I1 FR 23C1048 C FR23C1048 C FR 23C1048C FR 23C1048 C FR23C1048 C FR 23C1048C FR 23C1048 I1 FR23C1048 I1 FR 23C1048I1
Authority
FR
France
Prior art keywords
cachexia
treatment
receptor agonists
ghrelin receptor
ghrelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1048C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raqualia Pharma Inc
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of FR23C1048I1 publication Critical patent/FR23C1048I1/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR23C1048C 2010-02-26 2023-12-18 Agonistes de recepteur de ghreline pour la traitemnet de la cachexia Active FR23C1048I1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010043484 2010-02-26
PCT/JP2011/054556 WO2011105611A1 (fr) 2010-02-26 2011-02-28 Agoniste de récepteur de ghréline pour le traitement de la dyscrasie

Publications (1)

Publication Number Publication Date
FR23C1048I1 true FR23C1048I1 (fr) 2024-01-19

Family

ID=44507004

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1048C Active FR23C1048I1 (fr) 2010-02-26 2023-12-18 Agonistes de recepteur de ghreline pour la traitemnet de la cachexia

Country Status (13)

Country Link
US (2) US10975070B2 (fr)
EP (1) EP2540721B1 (fr)
JP (1) JPWO2011105611A1 (fr)
KR (1) KR20120131183A (fr)
CN (1) CN102762564B (fr)
BR (1) BR112012020377B1 (fr)
CA (1) CA2789750C (fr)
ES (1) ES2615731T3 (fr)
FR (1) FR23C1048I1 (fr)
HK (1) HK1174615A1 (fr)
MX (1) MX341660B (fr)
RU (1) RU2012141061A (fr)
WO (1) WO2011105611A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ746394A (en) 2012-09-27 2019-01-25 Aratana Therapeutics Inc Compositions and methods of use of an inappetance-controlling compound
MX360906B (es) * 2013-05-28 2018-11-21 Raqualia Pharma Inc Forma cristalina del l-tartrato de 2-amino-n[2-(3a-(r)- bencil-2-metil-3-oxo-2,3,3a,4,6,7-hexahidro-pirazolo[4,3-c]piridi n-5-il)-1-(r)-benciloximetil-2-oxo-etil]-isobutiramida.
CN106795158A (zh) * 2014-10-31 2017-05-31 拉夸里亚创药株式会社 作为生长激素释放肽受体激动剂的四氢吡唑并吡啶衍生物
KR20180108916A (ko) * 2015-01-28 2018-10-04 아라타나 세라퓨틱스, 인크. 체중-증량 화합물의 장기 사용을 위한 조성물 및 방법
KR20220039625A (ko) * 2020-09-22 2022-03-29 경북대학교 산학협력단 그렐린 수용체 작용제로서의 트리아졸 화합물의 용도
CN115778960A (zh) * 2022-08-19 2023-03-14 广州六顺生物科技有限公司 一种杂芳环衍生物在制备治疗或预防恶病质药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997984A (en) 1989-12-19 1991-03-05 Shawa Denko K.K. Process for preparation of N-(α-alkoxyethyl)-carboxylic acid amide
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
CA2576915A1 (fr) * 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Secretagogues d'hormone de croissance
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2008216789A1 (en) * 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
WO2008153027A1 (fr) * 2007-06-11 2008-12-18 Takeda Pharmaceutical Company Limited Dérivé de pyrroloquinoléine et son utilisation
WO2009063993A1 (fr) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited Dérivé de pyridine fusionné et son utilisation
WO2009139340A1 (fr) * 2008-05-12 2009-11-19 武田薬品工業株式会社 Composé pyrazole
NZ746394A (en) 2012-09-27 2019-01-25 Aratana Therapeutics Inc Compositions and methods of use of an inappetance-controlling compound

Also Published As

Publication number Publication date
EP2540721A4 (fr) 2013-08-07
WO2011105611A1 (fr) 2011-09-01
US20120322821A1 (en) 2012-12-20
US20210179613A1 (en) 2021-06-17
HK1174615A1 (en) 2013-06-14
JPWO2011105611A1 (ja) 2013-06-20
EP2540721B1 (fr) 2016-12-14
MX2012009774A (es) 2012-10-05
CN102762564B (zh) 2015-09-30
US10975070B2 (en) 2021-04-13
KR20120131183A (ko) 2012-12-04
RU2012141061A (ru) 2014-04-10
CN102762564A (zh) 2012-10-31
MX341660B (es) 2016-08-29
BR112012020377B1 (pt) 2019-10-08
EP2540721A1 (fr) 2013-01-02
ES2615731T3 (es) 2017-06-08
BR112012020377A8 (pt) 2018-01-02
CA2789750A1 (fr) 2011-09-01
CA2789750C (fr) 2018-03-06
BR112012020377A2 (pt) 2016-05-10

Similar Documents

Publication Publication Date Title
FR23C1048I1 (fr) Agonistes de recepteur de ghreline pour la traitemnet de la cachexia
ES1070518Y (es) Dispositivo nivelador para la colocacion de piezas de recubrimiento
EP2680853A4 (fr) Traitement du cancer par des antagonistes des récepteurs dopaminergiques
UA22227S (uk) Пристрій для обробляння води
DK2558105T3 (da) Bardoxolonmethyl til behandling af fedme
DK3718509T3 (da) Vævsanker til annuloplastikindretning
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
FR2955747B1 (fr) Moyen de reglage pour vetement
IL225758A0 (en) Preparations containing combinations of serotonin agonists and their uses
FR2978343B1 (fr) Organe d'ancrage pour materiel d'osteosynthese vertebrale
FR2968538B1 (fr) Prothese pour membre inferieur
IT1401941B1 (it) Dispositivo per imbarcazioni
HRP20150974T1 (en) 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors
HK1204286A1 (en) Ghrelin receptor agonists for the treatment of achlorhydria
EP2276345A4 (fr) Inhibiteurs de petites molécules du récepteur de l androgène
EP2533780A4 (fr) Agonistes du récepteur 5-ht4 pour le traitement de la démence
FR2971425B1 (fr) Dispositif de radioprotection pour seringue
FR2931916B1 (fr) Isolant pour bague
DE112011104236A5 (de) Knochenverankerungseinrichtung
ITMI20112151A1 (it) Apparecchio mobile automaticamente
DK2391366T3 (da) Substituerede benzimidazoler til behandling af astrocytomer
DK2597959T3 (da) Fremgangsmåde og indretning til afskalning af bløddyr
FR2959769B1 (fr) Dispositif de verrouillage pour un vantail semi-fixe
IT1403028B1 (it) Dispositivo per disabili
HK1202459A1 (en) Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders